Granted Patent
B2
US 12,440,548 · App. 18/598,439 · Granted Oct 14, 2025
Patent
Inventors:
Hun Kim (Suwon-si, KR); Dong Soo Ham (Suwon-si, KR); Jin-Hwan Shin (Seoul, KR); Kyung-Jun An (Seoul, KR); Sung-Hyun Kim (Yongin-si, KR)
Assignee:
SK BIOSCIENCE CO., LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae ; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.
Claims (9)
1. An immunogenic composition comprising a Streptococcus pneumoniae serotype 20 glycoconjugate in which a capsular polysaccharide from Streptococcus pneumoniae serotype 20 is conjugated to a carrier protein,
wherein the capsular polysaccharide is conjugated to the protein in a state where the capsular polysaccharide is activated to have a degree of oxidation of 4-16 and a molecular weight is 400-800 kDa.
2. The immunogenic composition according to claim 1 , wherein the glycoconjugate has a molecular weight of 1,000 to 4,000 kDa and the carrier protein is CRM 197 .
3. The immunogenic composition according to claim 1 , wherein the ratio of the capsular polysaccharide from serotype 20 to the carrier protein in the glycoconjugate is 1-5 (w/w).
4. The immunogenic composition according to claim 1 , wherein 70-90% of the glycoconjugate has a Kd of 0.3 or below as measured in a 4% Cross-linked Agarose beads (CL-4B) column.
5. The immunogenic composition according to claim 1 , wherein the immunogenic composition comprises a physiologically acceptable vehicle.
6. A vaccine comprising the immunogenic composition of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.
7. A method for treating infection or preventing or treating a disease or condition caused by Streptococcus pneumoniae serotype 20 in a subject, the method comprising administering an immunologically effective does of the immunogenic composition of claim 1 to the subject.
8. The method of claim 7 , wherein the infection, disease or condition caused by Streptococcus pneumoniae is selected from the group consisting of pneumonia, sinusitis, otitis media, acute otitis media, cerebromeningitis, bacteriemia, septicemia, pyothorax, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, mastoiditis, cellulitis, soft tissue infection and brain abscess.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 8, 2024
From: KIM, HUN; HAM, DONG SOO; SHIN, JIN-HWAN; AN, KYUNG-JUN; KIM, SUNG-HYUN
To: SK BIOSCIENCE CO., LTD.
Reel/Frame 067034/0170 →
Priority Claims (4)
KR 10-2018-0045245
· Apr 18, 2018
· national
KR 10-2018-0045246
· Apr 18, 2018
· national
KR 10-2018-0045247
· Apr 18, 2018
· national
KR 10-2018-0045248
· Apr 18, 2018
· national
Continuity (2)
Division
17047563
References Cited (182)
US 5153312A
· Porro
· 1992
[cited by applicant]
US 5773007A
· Penney et al.
· 1998
[cited by applicant]
US 6132723A
· Malcolm
· 2000
[cited by applicant]
US 6168796B1
· Malcolm
· 2001
[cited by applicant]
US 7709001B2
· Hausdorff et al.
· 2010
[cited by applicant]
US 7955605B2
· Prasad
· 2011
[cited by applicant]
US 8029798B2
· Leroy
· 2011
[cited by applicant]
US 20030099672A1
· Schultz
· 2003
[cited by applicant]
US 20110212124A1
· Boutriau et al.
· 2011
[cited by applicant]
US 20120052088A1
· Davis et al.
· 2012
[cited by applicant]
US 20120328659A1
· Denoel et al.
· 2012
[cited by applicant]
US 20130266609A1
· Boutriau
· 2013
[cited by applicant]
US 20150343076A1
· Park et al.
· 2015
[cited by applicant]
US 20210283247A1
· Hausdorff et al.
· 2021
[cited by applicant]
US 20220031828A1
· An et al.
· 2022
[cited by applicant]
US 20220265803A1
· An et al.
· 2022
[cited by applicant]
AU 2007200116A1
· 2007
[cited by applicant]
AU 2010235979A1
· 2010
[cited by applicant]
CA 2153730A1
· 1997
[cited by applicant]
CA 2153733A1
· 1997
[cited by applicant]
CN 1060408A
· 1992
[cited by applicant]
CN 1255861A
· 2000
[cited by applicant]
CN 101180079A
· 2008
[cited by applicant]
CN 101785857A
· 2010
[cited by applicant]
CN 101818185A
· 2010
[cited by applicant]
CN 102068690A
· 2011
[cited by applicant]
CN 102858365A
· 2013
[cited by applicant]
CN 103599529A
· 2014
[cited by applicant]
CN 103623401A
· 2014
[cited by applicant]
CN 103656631A
· 2014
[cited by applicant]
CN 103656632A
· 2014
[cited by applicant]
CN 107029225A
· 2017
[cited by applicant]
EP 0497524B1
· 1998
[cited by applicant]
EP 2932979A1
· 2015
[cited by applicant]
IN 201917040656
· 2019
[cited by applicant]
KR 1020120005537A
· 2012
[cited by applicant]
KR 1020130142574A
· 2013
[cited by applicant]
KR 1020140075201A
· 2014
[cited by applicant]
KR 1020160098507A
· 2016
[cited by applicant]
KR 1020170016360A
· 2017
[cited by applicant]
KR 101730749B1
· 2017
[cited by applicant]
KR 1020170102009A
· 2017
[cited by applicant]
KR 1020180027353A
· 2018
[cited by applicant]
KR 1020180105590A
· 2018
[cited by applicant]
TW 201008577A
· 2010
[cited by applicant]
TW 1341210B
· 2011
[cited by applicant]
WO 9640225A1
· 1996
[cited by applicant]
WO 9851339A1
· 1998
[cited by applicant]
WO 0056359A2
· 2000
[cited by applicant]
WO 0200249A2
· 2002
[cited by applicant]
WO 02080965A2
· 2002
[cited by applicant]
WO 2003051392A2
· 2003
[cited by applicant]
WO 2006032499A1
· 2006
[cited by applicant]
WO 2008079732A2
· 2008
[cited by applicant]
WO 2009000824A2
· 2008
[cited by applicant]
WO 2009000826A1
· 2008
[cited by applicant]
WO WO2009000825A2
· 2008
[cited by examiner]
WO 2010125480A1
· 2010
[cited by applicant]
WO 2011100151A1
· 2011
[cited by applicant]
WO 2013191459A1
· 2013
[cited by applicant]
WO 2014027302A1
· 2014
[cited by applicant]
WO 2014092377A1
· 2014
[cited by applicant]
WO 2014118201A1
· 2014
[cited by applicant]
WO 2015110940A2
· 2015
[cited by applicant]
WO 2015110941A2
· 2015
[cited by applicant]
WO 2015110942A2
· 2015
[cited by applicant]
WO 2015175355A1
· 2015
[cited by applicant]
WO 2016207905A2
· 2016
[cited by applicant]
WO 2017067962A1
· 2017
[cited by applicant]
WO 2017085586A1
· 2017
[cited by applicant]
WO 2017173415A2
· 2017
[cited by applicant]
WO 2018027123A1
· 2018
[cited by applicant]
WO 2018027126A1
· 2018
[cited by applicant]
WO 2018064444A1
· 2018
[cited by applicant]
WO 2019050813A1
· 2019
[cited by applicant]
WO 2019050815A1
· 2019
[cited by applicant]
WO 2019050816A1
· 2019
[cited by applicant]
WO 2019050818A1
· 2019
[cited by applicant]
WO 2019070994A1
· 2019
[cited by applicant]
WO 2019152921A1
· 2019
[cited by applicant]
WO 2019152925A1
· 2019
[cited by applicant]
WO 2021021729A1
· 2021
[cited by applicant]
Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. Oct. 201…
[cited by examiner]
Yano et al., “Characterization of Gene Use and Efficacy of Mose Monoclonal Antibodies to
[cited by applicant]
Buchwald et al., “A Peptide Mimotope of Type 8 PneumococcaCapsular Polysaccharide Induces a Protective Immune Response in Mice”, Infection and Immunity, 2005, vol. 73, No. 1, pp. 325-333.
[cited by applicant]
Malcolm et al., “Chapter 21: Surface Layers from Bacillus Alvei as a Carrier for a
[cited by applicant]
Malcolm et al., “Chapter 13: Crystalline Bacterial Cell Surface Layers (S-Layers) as Combined Carrier/Adjuvants for Conjugate Vaccines”, In: Sleytr U.B., Messner P., Pum D., Sára M. (eds) Immobilised Macromolecules: App…
[cited by applicant]
Malcolm et al., “S30: Improved Immunogenicity Using OligosaccharideConjugate Vaccines”, Glyco XIII: Xlllth International Symposium on Glycoconjugates; Seattle, USA, Aug. 20-26, 1995, Glycoconjugate Journal, 1995, vol. 1…
[cited by applicant]
Jahn-Schmid et al., “Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins”, Journal of Biotechnology, 1996, vol. 44, pp. 225-231.
[cited by applicant]
Thanos et al., “Invasive Infektion durch Streptococcus pneumoniae Serotyp 8 im Säuglingsalter”, Monatsschr Kinderheilkd, 2013, vol. 161, pp. 1177-1179, with English abstract.
[cited by applicant]
Office Action dated Aug. 10, 2020 for U.S. Appl. No. 16/322,698, 23 pages.
[cited by applicant]
Office Action dated Mar. 25, 2021 for U.S. Appl. No. 16/322,698, 13 pages.
[cited by applicant]
Office Action dated Mar. 15, 2021 for U.S. Appl. No. 16/322,726, 21 pages.
[cited by applicant]
International Search Report and Written Opinion dated Oct. 24, 2017 from International Application No. PCT/US2017/045483 (Authorized Officer, Blaine R. Copenheaver), 10 Pages.
[cited by applicant]
Durando et al., “Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults”, Clinical Microbiology Infection, Oct. 1, 2013, vol. 19, Suppl. 1, pp. 1-9.
[cited by applicant]
Daniels et al., “A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens”, J Pediatr Pharmacol Ther, 2016, vol. 21, No. 1, pp. 27-35.
[cited by applicant]
International Search Report and Written Opinion dated Oct. 30, 2017 from International Application No. PCT/US2017/045479 (Authorized Officer, Shane Thomas), 9 Pages.
[cited by applicant]
Jakobsen et al., “Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines Protects Mice against Invasive Pneumococcal Infections”, Infection and Immunity, Aug. 1999, vol. 67, No. 8, pp. 4128-4133.
[cited by applicant]
Prymula et al., “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both
[cited by applicant]
Dagan et al., “Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components”, Infection and Immunity, Sep. 20014, vol. 72, No. 9, pp. 5383-5…
[cited by applicant]
Fattom et al., “Serum Antibody Response in Adult Volunteers Elicited by Injection of Streptococcus pneumoniae Type 12F Polysaccharide Alone or Conjugated to Diphtheria Toxoid”, Infection and Immunity, Jul. 1990, vol. 58…
[cited by applicant]
Andrews et al., “Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study”, Lancet Infect Dis, Jul. 18, 2014, 8 pages.
[cited by applicant]
Juergens et al., “Post Hoc Analysis of a Randomized Double-Blind Trial of the Correlation of Functional and Binding Antibody Responses Elicited by 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines and Association w…
[cited by applicant]
Nurkka et al., “Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT”, Vaccine, 2002, vol. 20, pp. 194-201.
[cited by applicant]
Pfizer, “PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Suspension for intramuscular injection”, Prevnar 13 Full Prescribing Information, 2010, 47 pages.
[cited by applicant]
Vesikari et al., “Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine”, The Pediatric Infectious Disease Journal,…
[cited by applicant]
Wuorimaa et al., “Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults”, Vaccine, 2001, vol. 19, pp. 1863-1869.
[cited by applicant]
International Search Report and Written Opinion dated Apr. 15, 2019 from International Application No. PCT/US2019/016506 (Authorized Officer, Shane Thomas), 11 Pages.
[cited by applicant]
Extended European Search Report dated Mar. 10, 2020 for European Patent Application No. 17837752.9, 12 pages.
[cited by applicant]
Dagan et al., “Tolerability and immunogenicity of an eleven valent mixed carrier
[cited by applicant]
International Search Report and Written Opinion dated Jul. 1, 2019 from International Application No. PCT/US2019/016511 (Authorized Officer, Lee W. Young), 9 pages.
[cited by applicant]
Martens et al., “Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited”, BMC Infectious Diseases, 2004, vol. 4, No. 21, 7 pages.
[cited by applicant]
Sanofi's Opposition to Pfizer's Motion to Amend dated Nov. 16, 2018 from IPR Trial No. IPR2018-00187 for U.S. Pat. No. 9,492,559 (
[cited by applicant]
Loek Van Alphen, “Exhibit 1101, Declaration of Loek Van Alphen, PH.D. in Support of Sanofi's Opposition to Motion to Amend” dated Nov. 14, 2018 from IPR Trial No. IPR2018-00187 for U.S. Pat. No. 9,492,559 (
[cited by applicant]
Loek Van Alphen, “Exhibit 2073, Deposition of Loek Van Alphen, PH.D.” dated Dec. 10, 2018 from IPR Trial No. IPR2018-00187 for U.S. Pat. No. 9,492,559 (
[cited by applicant]
Peter R. Paradiso, “Exhibit 1116, Deposition of Peter R. Paradiso, PH.D.” dated Jan. 10, 2019 from IPR Trial No. IPR2018-00187 for U.S. Pat. No. 9,492,559 (
[cited by applicant]
Peter R. Paradiso, “Exhibit 2074, Declaration of Peter R. Paradiso, PH.D in Support of Pfizer's Reply in Support of Motion to Amend” dated Dec. 18, 2018 from IPR Trial No. IPR2018-00187 for U.S. Pat. No. 9,492,559 (
[cited by applicant]
Chen et al., “Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China”, BMJ …
[cited by applicant]
International Search Report and Written Opinion dated Apr. 11, 2020 from International Application No. PCT/US2020/043729, (Authorized Officer, N. Renggli-Zulliger), 12 pages.
[cited by applicant]
Beall et al., “A Population-Based Descriptive Atlas of Invasive Pneumococcal Strains Recovered Within the U.S. During 2015-2016”, Frontiers in Microbiology, Nov. 19, 2018, vol. 9, 19 pages.
[cited by applicant]
Van der Linden et al., “Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era”, BMC Infectious Diseases, May 5, 2015, vol. 15, No. 1, p. 207, 12 pages.
[cited by applicant]
Non-Final Office Action dated May 3, 2023 for U.S. Appl. No. 17/471,825, 51 pages.
[cited by applicant]
Dagan et al., “Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components”, Infection and Immunity, Sep. 2004, vol. 72, No. 9, pp. 5383-53…
[cited by applicant]
N. Renggli-Zulliger (Authorized Officer), International Search Report and Written Opinion dated Nov. 4, 2020 for International Application No. PCT/US2020/043729, 12 pages.
[cited by applicant]
International Search Report dated Jul. 16, 2019 for International Patent Application No. PCT/KR2019/004717, 20 pages with English translation.
[cited by applicant]
Bethell et al., “A Novel Method of Activation of Cross-linked Agaroses with 1,1′-Carbonyldiimidazole Which Gives a Matrix for Affinity Chromatography Devoid of Additional Charged Groups”, The Journal of Biological Chemi…
[cited by applicant]
Extended European Search Report dated Mar. 18, 2022 for European Patent Application No. 19748037.9, 12 pages.
[cited by applicant]
Extended European Search Report dated Mar. 18, 2022 for European Patent Application No. 19747393.7, 12 pages.
[cited by applicant]
Anderson et al., “Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children,” VACCINE, 2003, vol. 21, No. 13-14, pp. 1554-1559.
[cited by applicant]
Sigurdardottir et al., “Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine,” The Pediatric Infectious Disease…
[cited by applicant]
Wuorimaa et al., “Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers,” The Pediatric Infectious Disease Journal, 2001, vol. 20, No. 3, pp. 272-277.
[cited by applicant]
Extended European Search Report dated Mar. 16, 2022 for European Patent Application No. 19788873.8, 14 pages.
[cited by applicant]
Boot et al., “Simultaneous vaccination with Prevenar and multicomponent vaccines for children: Interference or no interference?”, Human Vaccines, 2009, vol. 5, No. 1, pp. 15-17.
[cited by applicant]
Kovtun et al., “Next Generation Pneumococcal Conjugate Vaccines Efficacy in Different Regions of the World”, Current Pediatrics, 2014, vol. 13, No. 1, pp. 18-25 with English Abstract.
[cited by applicant]
Kolberg et al., “Monoclonal antibodies with specifities for
[cited by applicant]
Nuriev et al., “Immunochemical and Protective Properties of Conjugated Capsular Polysaccharide of
[cited by applicant]
Office Action dated Jul. 9, 2024 for Japanese Patent Application No. 2023-117178, 6 pages with English translation.
[cited by applicant]
Notice of Allowance and Examiner-Initiated Interview Summary dated May 11, 2021 for U.S. Appl. No. 16/966,584, 21 pages.
[cited by applicant]
Notice of Allowance and Examiner-Initiated Interview Summary dated May 12, 2021 for U.S. Appl. No. 16/966,552, 20 pages.
[cited by applicant]
Notice of Allowance dated Sep. 14, 2021 for U.S. Appl. No. 16/966,552, 14 pages.
[cited by applicant]
Notice of Allowance dated Aug. 18, 2021 for U.S. Appl. No. 16/966,584, 14 pages.
[cited by applicant]
Non-Final Office Action dated Jul. 16, 2024 for U.S. Appl. No. 17/500,716, 54 pages.
[cited by applicant]
Final Office Action dated Aug. 2, 2023 for U.S. Appl. No. 17/471,825, 12 pages.
[cited by applicant]
Notice of Allowance and Examiner-Initiated Interview Summary dated Oct. 24, 2023 for U.S. Appl. No. 17/471,825, 8 pages.
[cited by applicant]
Office Action dated May 3, 2023 for U.S. Appl. No. 17/471,825, 51 pages.
[cited by applicant]
Notice of Allowance and Applicant-Initiated Interview Summary dated Sep. 23, 2021 for U.S. Appl. No. 16/322,698, 8 pages.
[cited by applicant]
Notice of Allowance dated Oct. 20, 2021 for U.S. Appl. No. 16/322,698, 14 pages.
[cited by applicant]
Notice of Allowance dated Sep. 7, 2021 for U.S. Appl. No. 16/322,726, 13 pages.
[cited by applicant]
Notice of Allowance dated Oct. 29, 2021 for U.S. Appl. No. 16/322,726, 18 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/500,716 dated Dec. 16, 2024, 16 pages.
[cited by applicant]
Office Action for U.S. Appl. No. 17/630,841 dated Dec. 6, 2024, 18 pages.
[cited by applicant]
Written Opinion and Search Report dated Sep. 6, 2024 for Taiwan Patent Application No. 112144714, 12 pages including (Machine) English translation.
[cited by applicant]
Liang, Yongzhuo (CN Examiner), Chinese Search Report for Chinese Application No. 202080061473.6 dated Apr. 30, 2025, 4 pages including English translation.
[cited by applicant]
Fredman, Jeffrey N., et al. (Administrative Patent Judges for U.S. Patent and Trademark Office, Patent Trial and Appeal Board, “Judgment—Final Written Decision on Remand, Denying Patent Owner's Motion to Amend as to Pro…
[cited by applicant]
Gutman, Siegmund Y., et al. (Counsel for Appellees Sanofi Pasteur Inc et al.), “Appellees Sanofi Pasteur Inc., and SK Chemicals Co., Ltd's Responsive Brief,”
[cited by applicant]
Lourie et al. (Circuit Judges for U.S. Court of Appeals for the Federal Circuit), “Decision on Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2017-02131, IPR2017-021…
[cited by applicant]
Navarro, Albert M. (Examiner), Office Action for U.S. Appl. No. 18/419,900 dated May 2, 2025, 9 pages.
[cited by applicant]
Shahnan Shah, Khatol S. (Examiner), Final Office Action for U.S. Appl. No. 17/630,841 dated Jun. 18, 2025, 31 pages.
[cited by applicant]
Cited By (1)